This study aims to evaluate balance ability, core stability, functional capacity, lower extremity muscle strength, and fatigue levels in children diagnosed with central nervous system demyelinating diseases, in order to contribute to the development of evidence-based and individualized rehabilitation strategies.

Central nervous system demyelinating diseases in childhood, including multiple sclerosis, neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelitis, are rare but may result in significant physical and cognitive impairments. These conditions arise from immune-mediated damage to the white matter of the brain, optic nerve, and spinal cord, leading to disruptions in neuromotor development.

Motor dysfunction, fatigue, and reduced physical activity are commonly observed in affected children and are associated with decreased functional capacity and quality of life. In addition, impaired postural stability due to disrupted integration of proprioceptive, vestibular, and visual systems contributes to balance deficits, increased fall risk, gait abnormalities, and reduced participation in daily activities.

Core stabilization plays a fundamental role in motor development and functional movement by ensuring efficient postural control and force transfer through the kinetic chain. However, central nervous system pathology may impair the timely and coordinated activation of core musculature.

Despite growing literature in adult populations, pediatric evidence remains limited, which restricts the development of individualized rehabilitation approaches. Therefore, this study will assess balance, core stability, functional capacity, lower extremity muscle strength, and fatigue in children with demyelinating diseases to better inform clinical rehabilitation strategies.

Inclusion Criteria:

• Age between 6 and 18 years
• Diagnosed with a pediatric demyelinating disease
• No relapse within the last 3 months
• No botulinum toxin (Botox) injections within the last 3 months
• No corticosteroid treatment within the last 3 months
• Ability to read and write

Exclusion Criteria:

• History of concomitant autoimmune diseases
• Refusal of the patient and/or caregiver to participate in the study
• History of another primary neurological disease
• Cognitive impairment that limits understanding of instructions and participation in assessments
• Visual and/or hearing impairments that interfere with activities of daily living
• Presence of additional rheumatological conditions that may interfere with assessments
• Spasticity grade ≥2 according to the Modified Ashworth Scale in any muscle group

The study will be conducted with pediatric patients diagnosed with demyelinating diseases (Multiple Sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)) who are referred to our center.

No, individual participant data (IPD) will not be shared. All study records will be destroyed 2 years after study completion.